Nucleic Acid Insights


Welcome to Nucleic Acid Insights! 

Nucleic acids received a major boost through the ‘proof of concept’ delivered by the tremendously successful COVID-19 vaccines. As a result, investment is flooding in, driving new applications and opportunities. However, this remains a nascent field, which lacks a dedicated provider of both high-level analysis and in-depth technical data. 

Nucleic Acid Insights is specifically designed to give you the understanding and need-to-know information you require to successfully navigate this rapidly evolving space – your go-to online resource keeping you up to date with all the latest news, trends, issues, and breakthroughs across the nucleic acids area.

Click here for the Editorial Calendar.

Nucleic Acid Insights will feature specifically commissioned new content, whilst also forming a central repository of relevant content from BioInsights’ three current journals: Cell & Gene Therapy Insights, Immuno-Oncology Insights, and Vaccine Insights

Nucleic Acid Insights will cover all the major RNA and DNA technologies and modalities, including, but not limited to:

  • Messenger RNA (mRNA)
  • Plasmid DNA
  • Antisense oligonucleotides (ASO)
  • Phosphorodiamidate morpholino oligonucleotides (PMO) 
  • RNA interference (RNAi)
  • Small interfering RNA (siRNA)
  • Aptamers
  • Micro RNA (miRNA)
  • Guide RNA (gRNA)

Furthermore, we will provide BioInsights members with both a ‘big picture’ snapshot of the field as a whole and its component parts, and detailed, data-rich technical/scientific content.

BioInsights members will receive a weekly e-newsletter with the latest featured content, allowing you to efficiently review and pick out topics and formats of greatest interest and relevance.  

Nucleic Acid Insights will meet the needs of both current experts and new arrivers in the nucleic acids area, working in academia, pharma and biotech, and the tools and services sector. It will also cater for external stakeholders including analysts and investors, payers and HTAs, regulators, NGOs, and patient advocacy groups. 

For more information or to discuss thought leadership and lead generation opportunities, contact Nicola McCall at